Navigation Links
Amnis Announces Release of Powerful New Image Data Analysis Software
Date:4/10/2008

SEATTLE, April 10 /PRNewswire/ -- Amnis Corporation announced today a major new release of its IDEAS(R) statistical image analysis software. IDEAS version 3.0 incorporates greatly expanded analytical capabilities while maintaining an emphasis on ease of use.

IDEAS 3.0 provides the user with dozens of new image feature calculations and improves existing features to strengthen morphological data analysis. The new software also provides the user with much greater flexibility in defining specific areas of interest within a cell with eight new masking functions. Finally, ease of use has been improved with a new fluorescence crosstalk compensation process, automated statistical summaries of batch-processed data, and an all-new wizard system. Amnis is providing IDEAS 3.0 at no charge to all ImageStream sites that are under warranty or service contract.

"The commercial release of IDEAS 3.0 is a major accomplishment for Amnis," said David Basiji, Ph.D., Amnis' President and CEO. "By making the IDEAS software more powerful and easier to use, we're working to bring the benefits of quantitative cell image analysis to an even wider audience. This release lays the foundation for future versions that will make image data analysis far faster, more intuitive, and more automated."

Cathy Zimmerman, Amnis' Director of Software, added, "Our software team works closely with customers and with the scientists at Amnis to insure that we are developing the most relevant and useful tools possible. We have been very gratified by the exceptionally positive response this release has received so far."

Amnis Corporation, headquartered in Seattle, WA, develops, manufactures and markets the ImageStream system for high speed imaging of cells in flow. The system generates six high resolution microscopic images of cells as they flow through the instrument at rates up to 300 cells per second. The system is unique in its ability to image tens of thousands of cells in mi
'/>"/>

SOURCE Amnis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
2. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
3. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
4. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
5. ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis
6. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
7. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
8. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
9. Oncothyreon announces effectiveness of shelf registration statement
10. Novagali Pharma Announces the Launch of Cationorm(R)
11. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... Shionogi-ViiV Healthcare, LLC announced today that the first ... designed to support a new fixed-dose combination (FDC) ... investigational regimen, known as 572-Trii, will combine the ... combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... TRIANGLE PARK, N.C., Feb. 2, 2011 The day ... off the shelf for use in life-saving vascular surgeries ... published in the current issue of the journal, ... vascular grafts (TEVGs) that are immediately-available at the time ...
... Inc. (Nasdaq: SGMO ) today reported fourth quarter ... For the fourth quarter ended December 31, 2010, Sangamo ... per share, compared to a net loss of $2.4  million, ... As of December 31, 2010, the company had cash, cash ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis 2Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:8/21/2014)... team has successfully replicated one of the crucial steps ... by sunlight which could manufacture hydrogen as a fuel. ... is an exciting prospect to use them to create ... Kastoori Hingorani, from the ARC Centre of Excellence for ... , Hydrogen offers potential as a zero-carbon replacement for ...
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
(Date:8/20/2014)... population-based screening outcomes of approximately 3 million infants, a ... at the University of Massachusetts Medical School, have shown ... be successfully implemented across public health newborn screening programs. ... Aug. 20 issue of the Journal of the ... rate of SCID in newborns is higher than previously ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... the Faculty of Veterinary Medicine at Universitat Autnoma ... Research in Agricultural Genomics (CRAG), the Centre for ... for Agrarian Technology and Research in Madrid and ... the first partial genome sequencing of an Iberian ...
... The debate surrounding carbon capture and storage intensifies as ... Berkeley National Laboratory (Berkeley Lab) examine the capacity for ... in the new journal Greenhouse Gases: Science & ... the conclusions drawn in an earlier study by Ehlig-Economides ...
... biochemistry is how proteins recognize "correct" interaction partners in ... critical to know than in the brain, where interactions ... A team of biologists at the Salk Institute for ... regulates availability of a brain channel that modulates neuronal ...
Cached Biology News:First partial sequencing of an Iberian pig 2Carbon capture and storage: Carbon dioxide pressure dissipates in underground reservoirs 2Salk scientists crack molecular code regulating neuronal excitability 2Salk scientists crack molecular code regulating neuronal excitability 3
...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
Biology Products: